Are you living with Tenosynovial Giant Cell Tumors (TGCT)?

If so, you may be eligible for a clinical trial

Are you living with Tenosynovial Giant Cell Tumors (TGCT)? If so, you may be eligible for a clinical trial

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Tenosynovial Giant Cell Tumor Clinical Trial
NCT03069469 | Phase 1 | Interventional

Are you living with Tenosynovial Giant Cell Tumors (TGCT)?

If so, you may be eligible for a clinical trial

Are you living with Tenosynovial Giant Cell Tumors (TGCT)? If so, you may be eligible for a clinical trial


Male & Female

18 Years +

This study is looking to recruit about 102 Participants

One aspect of this clinical trial focuses on patients living with Diffuse Tenosynovial Giant Cell Tumor (DTGCT). This trial will evaluate the effectiveness and tolerable dosage of an oral investigational drug called “DCC-3014”.

What is the purpose of this clinical trial?

By enrolling in this Phase I trial, you will help us understand:
■ The tolerable dose of the investigational drug, DCC-3014
■ If there are any side effects from taking DCC-3014
■ The anti-tumor activity of DCC-3014

Throughout this trial, we will evaluate the medicine’s effects on tumor activity by MRI scans, the patient’s range of motion (ROM), and patient reported outcomes (answering questionnaires) regarding pain and physical functioning.

What's involved?

If you would like more information about this clinical trial, please select the blue “I’m Interested” button and enter your contact information. Once you do so, a representative from our call center will reach out to you and ask you a few questions about yourself and your condition. If you are eligible, we will then connect you with the nearest clinical site to where you live.

Prior to enrolling in the DTGCT trial, you will need to understand the nature of the trial by speaking with the study staff and reading the Informed Consent Form (ICF). The ICF provides a description of the clinical trial, the procedures you will undergo during the trial to find out if you are eligible to participate, and the known safety information of the study drug. The study doctor and study team will be available to answer questions that you or your family might have as you go through the process.

Who can participate?

To qualify for the DTGCT trial, the patient must:
■ Have a confirmed diagnosis of Diffuse Tenosynovial Giant Cell Tumor, DTGCT (formerly known as Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath)
■ Test negative for pregnancy (female participants of child-bearing potential)
■ Be 18 years of age or older

This is not a complete list of participation criteria and other inclusion/exclusion criteria may apply.

Frequently Asked Questions
What is Tenosynovial Giant Cell Tumor?

Tenosynovial Giant Cell Tumors (TGCT) are a group of benign tumors that involve the synovium, bursae and/or tendon sheath. Although benign, these tumors can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint. Surgery is the main treatment option; however, these tumors tends to recur, particularly in pigmented villonodular synovitis, a diffuse-type of TGCT. If untreated or if the tumor continually recurs damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability.

This study is seeking to enroll diffuse TGCT patients.

Where is this trial conducted?

This trial is being conducted at multiple research site locations. Currently, there are research sites located in Portland, OR and Denver, CO. There are also sites that are currently in the process of opening in New York City, Palo Alto, CA, Jacksonville, FL, Toronto, Canada, and other locations in the coming months.

How will the study drug be administered?

The study drug, DCC-3014, is a capsule that is administered orally.

Is there a risk that I will receive a placebo?

This study doesn’t have a placebo so everyone participating in the study will receive the study drug.

Interested in learning more?

To get started, please choose a location